LY3437943 entered the published literature under the development code LY3437943, and by now a handful of papers cover its receptor pharmacology, its behavior in rodent models, and several clinical trials. This article works through what each of those papers actually measured, its model or study population, and its stated endpoints, without repeating the structural or mechanistic background covered in the site's other LY3437943 articles. Treat this as a reading guide to the primary literature rather than a restatement of any single paper's conclusions.
| Paper | Study type | What it measured |
|---|---|---|
| Coskun et al., 2022 | Discovery pharmacology through early clinical proof of concept | Receptor potency, rodent and primate metabolic endpoints, first human pharmacokinetics |
| Knerr et al., 2022 | Preclinical, diet-induced obese mice | Body weight change versus dual-receptor comparator molecules |
| Urva et al., 2022 | Phase 1b, people with type 2 diabetes | Multiple-ascending-dose safety, pharmacokinetics and pharmacodynamics |
| Urva et al., 2023 | Clinical pharmacology substudy | Gastric emptying rate |
| Rosenstock et al., 2023 | Phase 2, people with type 2 diabetes | Glycemic and body weight endpoints versus placebo and an active comparator |
| Jastreboff et al., 2023 | Phase 2, participants with obesity | Body weight change over 48 weeks versus placebo |
| Wen et al., 2025 | Biomarker substudy | Circulating ANGPTL3/8 concentrations alongside serum lipid changes |
What did the original discovery paper establish?
Coskun and colleagues published the paper that introduced LY3437943's full pharmacological profile, describing the compound's design, its in vitro potency at the GLP-1, GIP and glucagon receptors, its behavior in rodent and non-human primate metabolic models, and its earliest human pharmacokinetic data in a single continuous body of work (Coskun et al., 2022). That paper is the reference point nearly every later LY3437943 study cites for the molecule's baseline pharmacology, which is why it is worth reading first before any of the later, narrower clinical papers. The receptor-level detail from that paper is covered separately in the site's article on LY3437943's triple agonist mechanism, and the molecule's structural identity is covered in what is LY3437943.
What did the preclinical mouse study add beyond the discovery paper?
Knerr and colleagues ran a dedicated comparison in diet-induced obese mice, testing a GLP-1/GIP/glucagon triple agonist against dual-receptor comparator molecules and tracking body weight change as the primary readout across the study period (Knerr et al., 2022). The value of a paper like this is the head-to-head design: rather than reporting one molecule's effect in isolation, it places the triple-receptor approach next to the dual-receptor alternative in the same model, which is the kind of comparison a single-molecule discovery paper is not built to provide on its own.
What did the phase 1b trial in people with type 2 diabetes measure?
Urva and colleagues' phase 1b trial was a multiple-ascending-dose study in participants with type 2 diabetes, structured to characterize safety, pharmacokinetics and pharmacodynamics across a range of dose levels rather than to establish clinical benefit (Urva et al., 2022). Multiple-ascending-dose designs are an early-phase tool: their job is to map out how a compound behaves in the body and what a well-tolerated dose range looks like, ahead of the larger, endpoint-driven trials that follow. The pharmacokinetic figures from this trial, including the reported elimination half-life, are covered in more detail in the site's article on LY3437943's structure and half-life.
What did the gastric emptying substudy specifically test?
Urva and colleagues published a separate, narrower clinical pharmacology paper focused specifically on gastric emptying rate, reporting that LY3437943 delayed this process, a finding consistent with GLP-1 receptor pharmacology (Urva et al., 2023). This kind of substudy illustrates how the published literature on a single molecule tends to fragment: the big discovery and phase 2 papers cover broad endpoints, while smaller mechanistic substudies isolate one physiological readout at a time to test whether it behaves as receptor pharmacology would predict.
What did the phase 2 trials in type 2 diabetes and in obesity measure?
Rosenstock and colleagues ran a randomized, placebo- and active-comparator-controlled phase 2 trial in people with type 2 diabetes, reporting glycemic and body weight endpoints across the trial's dose groups (Rosenstock et al., 2023). Jastreboff and colleagues ran a parallel phase 2 trial in participants with obesity, reporting body weight change over a 48-week study period compared with placebo (Jastreboff et al., 2023). Both are randomized, controlled efficacy trials, a different tier of evidence from the earlier pharmacology and pharmacokinetic papers: they are designed and powered to test whether an effect exists against a comparator group, not simply to characterize the molecule's behavior. Readers comparing figures across the two trials should note that the participant populations, dose groups and trial durations differ, which is part of why the two papers report different absolute numbers for related endpoints.
What did the more recent biomarker substudy examine?
Wen and colleagues' more recent paper looked at a specific pair of circulating proteins, ANGPTL3 and ANGPTL8, in participants who had received LY3437943 in a trial setting, reporting that decreases in these markers paralleled the reductions in serum lipids observed in the same participants (Wen et al., 2025). Papers like this one are downstream of the main efficacy trials: once a body-weight or glycemic effect has been established in the primary trials, substudies like this one dig into candidate biological mechanisms that might explain a secondary observation, in this case a lipid-related one, rather than re-testing the primary endpoint itself.
Where can a researcher source LY3437943 for this kind of bench work?
Homegrown supplies LY3437943 as a lyophilized powder for laboratory research, with lot-specific specifications and the current certificate of analysis posted on the LY3437943 product page.
Frequently asked questions
Which LY3437943 paper should a researcher read first?
Coskun and colleagues' 2022 discovery paper, since it establishes the pharmacology, preclinical models and earliest clinical data that essentially every later paper builds on or references (Coskun et al., 2022).
Are the phase 2 trials the same as regulatory approval studies?
No. Phase 2 trials, such as the ones reported by Rosenstock and colleagues and by Jastreboff and colleagues, are mid-stage efficacy and dose-finding trials. They are a step in a clinical development program, not a final regulatory approval, and LY3437943's status in that program can be checked directly against the primary trial publications rather than assumed from them.
What is the difference between a multiple-ascending-dose trial and a phase 2 efficacy trial?
A multiple-ascending-dose trial, like Urva and colleagues' 2022 phase 1b study, is designed to characterize safety and pharmacokinetics across a dose range in a smaller group. A phase 2 efficacy trial, like the Rosenstock or Jastreboff papers, is a larger, randomized, controlled study designed to test whether a specific endpoint differs from placebo or a comparator.
Do the animal studies use the same endpoints as the human trials?
Not exactly. Knerr and colleagues' mouse study tracked body weight change in a diet-induced obesity model, which is a useful preclinical analog but not identical in design or measurement to the body weight and glycemic endpoints reported in the human phase 2 trials.
Is the ANGPTL3/8 substudy a new clinical trial or an analysis of existing trial data?
It is a biomarker analysis conducted using samples and data from participants in an existing LY3437943 trial, examining a specific mechanistic question about lipid metabolism rather than constituting a new standalone efficacy trial (Wen et al., 2025).
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PubMed 35985340.
- Knerr PJ, Mowery SA, Douros JD, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022;63:101533. PubMed 35809773.
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. PubMed 36354040.
- Urva S, O'Farrell L, Du Y, et al. The novel GIP, GLP-1 and glucagon receptor agonist LY3437943 delays gastric emptying. Diabetes Obes Metab. 2023;25(9):2784-2788. PubMed 37311727.
- Rosenstock J, Frias J, Jastreboff AM, et al. LY3437943, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PubMed 37385280.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist LY3437943 for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PubMed 37366315.
- Wen Y, Lemen D, Lin Y, et al. Decreases in circulating ANGPTL3/8 concentrations following LY3437943 treatment parallel reductions in serum lipids. Diabetes Obes Metab. 2025;27(10):5985-5995. PubMed 40726454.
Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.
